Adicet Bio Seeks to Join Clinical Trial Stage for Lupus Therapies

News
Article

ADI-001 is also being evaluated in a phase 1 study in patients with B-cell non-Hodgkin lymphoma.

Adicet Bio has received Fast Track Designation for its allogeneic gamma delta T cell therapy ADI-001 for treating relapsed/refractory class III or class IV lupus nephritis, joining the race of clinical-stage candidates being developed for autoimmune diseases.1

“The FDA’s decision to grant ADI-001 Fast Track Designation for lupus nephritis underscores the urgent need for new therapies for this chronic disease,” Chen Schor, President and Chief Executive Officer, Adicet Bio, said in a statement.1 “We plan toinitiate our Phase 1 clinical study in lupus nephritis later this month. With clinical data for ADI-001 in non-Hodgkin’s lymphoma demonstrating CD19+ B-cell depletion that mirrors data by autologous alpha-beta chimeric antigen receptor (CAR) T in academic clinical studies in several autoimmune diseases, we believe we are well positioned to expand our autoimmune program to address additional indications beyond lupus nephritis. We look forward to providing a comprehensive update on our autoimmune program to investors in the near term.”

Adicet originally developed ADI-001 for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), for which it is being evaluated in a phase 1 study (NCT04735471). The company announced positive interim data from the study in June 2023, boasting an overall complete response (CR) rate of 63%, a 6-month CR rate of 25%, and a CR rate of 67% and 6-month CR rate of 33%in patients whose disease had progressed after CD19 CAR T-cell therapy.2

“We plan to transition the ADI-001 program into a potential pivotal Phase 2 study in post-CAR T LBCL in the first half of 2024. In addition, we expect to provide a clinical update which will include efficacy, 6-month CR rate, and safety data, from additional post-CAR T LBCL patients in the second half of 2024,” Francesco Galimi, MD, PhD, Senior Vice President and Chief Medical Officer of Adicet Bio, noted in a statement.2

READ MORE: World Lupus Day 2024: Looking Back at a Year of New Cell Therapy IND Clearances

In other recent news in the lupus space, Cabaletta Bio’s CABA-201, an investigational CD19-directed CAR T-cell therapy, recently demonstrated initial safety data in participants with systemic lupus erythematosus (SLE) and lupus nephritis in the phase 1/2 RESET-SLE clinical trial (NCT06121297). The first patients dosed have completed their 28-day dose-limiting toxicity observation window after receiving the CAR-T, with neither patient showing evidence of any grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).

“With no CRS or ICANS of any grade observed in either of the first patients from the RESET-Myositis and RESET-SLE trials, we look forward to presenting initial translational and clinical data from both patients during a satellite symposium at the EULAR 2024 Congress on June 14th,” Steven Nichtberger, MD, the chief executive officer and cofounder of Cabaletta, said in a statement.3

REFERENCES
1. Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis. News release. Adicet Bio. June 5, 2024. https://www.businesswire.com/news/home/20240605481965/en/Adicet-Bio-Receives-FDA-Fast-Track-Designation-for-ADI-001-in-Lupus-Nephritis
2. Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL). News release. Adicet Bio. June 26, 2023. https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-reports-positive-data-ongoing-adi-001-phase-1-trial-0
3. Cabaletta Bio reports first quarter 2024 financial results and provides business update. News release. Cabaletta Bio, Inc. May 15, 2024. https://www.cabalettabio.com/news-media/press-releases/detail/110/cabaletta-bio-reports-first-quarter-2024-financial-results
Related Videos
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Marcus Conant, MD, on More Research Needed With HIV Therapies
© 2024 MJH Life Sciences

All rights reserved.